Correlation of phospholipid metabolites with prostate cancer pathologic grade, proliferative status and surgical stage - impact of tissue environment

NMR in Biomedicine

Volumn 24, Issue 6, 2011, Pages 691-699

  Keshari, K R ^a   Tsachres, H ^a   Iman, R ^a   Delos Santos, L ^a   Tabatabai, Z L ^a   Shinohara, K ^b   Vigneron, D B ^a   Kurhanewicz, J ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Gleason score; Ki 67; Pathologic grade; Phospholipid metabolism; Prostate cancer; Stage; Tumor microenvironment

Indexed keywords

GLEASON SCORES; KI-67; PATHOLOGIC GRADE; PROSTATE CANCERS; TUMOR MICROENVIRONMENT;

CELL CULTURE; CELL PROLIFERATION; HISTOLOGY; METABOLISM; METABOLITES; PATHOLOGY; PHOSPHOLIPIDS; SURGERY; TISSUE; UROLOGY;

DISEASES;

GLYCEROPHOSPHOETHANOLAMINE; GLYCEROPHOSPHORYLCHOLINE; KI 67 ANTIGEN; PHOSPHOETHANOLAMINE; PHOSPHOLIPID; PHOSPHORYLCHOLINE;

ADULT; AGED; ARTICLE; CANCER LOCALIZATION; CANCER PATIENT; CANCER SURGERY; CANCER TISSUE; CELL CULTURE; CELL INTERACTION; CELL PROLIFERATION; CLINICAL ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE SEVERITY; GLEASON SCORE; HIGH RESOLUTION MAGIC ANGLE SPINNING TOTAL CORRELATION SPECTROSCOPY; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PHOSPHOLIPID METABOLISM; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE EPITHELIUM; PROSTATE HYPERTROPHY; PROSTATECTOMY; PROTON NUCLEAR MAGNETIC RESONANCE; STROMA CELL;

AGED; CELL PROLIFERATION; CHOLINE; ETHANOLAMINE; HUMANS; KI-67 ANTIGEN; MALE; NEOPLASM STAGING; PHOSPHOLIPIDS; PROSTATE; PROSTATIC NEOPLASMS; TUMOR MICROENVIRONMENT;

EID: 79960829692     PISSN: 09523480     EISSN: 10991492     Source Type: Journal    
DOI: 10.1002/nbm.1738     Document Type: Article

References (53)

1. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer. J. Clin. 2010; 60: 277-300.
2. McNeal JE, Bostwick DG, Kindrachuk RA, Redwine EA, Freiha FS, Stamey TA. Patterns of progression in prostate cancer. Lancet, 1986; 1(8472): 60-63.
3. Stamey TA. Cancer of the prostate: an analysis of some important contributions and dilemmas. Mono. Urol. 1982; 3: 67-94.
4. Hu JC, Elkin EP, Pasta DJ, Lubeck DP, Kattan MW, Carroll PR, Litwin MS. Predicting quality of life after radical prostatectomy: results from CaPSURE. J. Urol. 2004; 171(2 Pt 1): 703-707, discussion 707-708.
5. Wei JT, Dunn RL, Sandler HM, McLaughlin PW, Montie JE, Litwin MS, Nyquist L, Sanda MG. Comprehensive comparison of health-related quality of life after contemporary therapies for localized prostate cancer. J. Clin. Oncol. 2002; 20(2): 557-566.
6. Gleason D. Histologic grading of prostate cancer: a perspective. Hum. Pathol. 1992; 23: 273-279.
7. Wills ML, Sauvageot J, Partin AW, Gurganus R, Epstein JI. Ability of sextant biopsies to predict radical prostatectomy stage. Urology, 1998; 51(5): 759-764.
8. Egevad L, Granfors T, Karlberg L, Bergh A, Stattin P. Percent Gleason grade 4/5 as prognostic factor in prostate cancer diagnosed at transurethral resection. J. Urol. 2002; 168(2): 509-513.
9. Feneley MR, Young MP, Chinyama C, Kirby RS, Parkinson MC. Ki-67 expression in early prostate cancer and associated pathological lesions. J. Clin. Pathol. 1996; 49(9): 741-748.
10. Pollack A, DeSilvio M, Khor L, Li R, Al-Saleem T, Hammond M, Venkatesan V, Byhardt R, Hanks GE, Roach M, Shipley WU, Sandler HM. Ki-67 staining is a strong predictor of patient outcome for prostate cancer patients treated with androgen deprivation plus radiotherapy: an analysis of RTOG 92-02. Int. J. Radiat. Oncol. Biol. Phys. 2003; 57(2 Suppl): S200-S201.
11. Kurhanewicz J, Swanson MG, Nelson SJ, Vigneron DB. Combined magnetic resonance imaging and spectroscopic imaging approach to molecular imaging of prostate cancer. J. Magn. Reson. Imaging, 2002; 16(4): 451-463.
12. Kurhanewicz J, Vigneron D, Carroll P, Coakley F. Multiparametric magnetic resonance imaging in prostate cancer: present and future. Curr. Opin. Urol. 2008; 18(1): 71-77.
13. Casciani E, Polettini E, Bertini L, Emiliozzi P, Amini M, Pansadoro V, Gualdi GF. Prostate cancer: evaluation with endorectal MR imaging and three-dimensional proton MR spectroscopic imaging. Radiol. Med. 2004; 108(5-6): 530-541.
14. Kumar R, Kumar M, Jagannathan NR, Gupta NP, Hemal AK. Proton magnetic resonance spectroscopy with a body coil in the diagnosis of carcinoma of the prostate. Urol. Res. 2004; 32(1): 36-40.
15. Zakian KL, Sircar K, Hricak H, Chen HN, Shukla-Dave A, Eberhardt S, Muruganandham M, Ebora L, Kattan MW, Reuter VE, Scardino PT, Koutcher JA. Correlation of proton MR spectroscopic imaging with Gleason score based on step-section pathologic analysis after radical prostatectomy. Radiology, 2005; 234(3): 804-814.
16. Podo F. Tumour phospholipid metabolism. NMR Biomed. 1999; 12(7): 413-439.
17. Ackerstaff E, Pflug BR, Nelson JB, Bhujwalla ZM. Detection of increased choline compounds with proton nuclear magnetic resonance spectroscopy subsequent to malignant transformation of human prostatic epithelial cells. Cancer Res. 2001; 61(9): 3599-3603.
18. Glunde K, Ackerstaff E, Mori N, Jacobs MA, Bhujwalla ZM. Choline phospholipid metabolism in cancer: consequences for molecular pharmaceutical interventions. Mol. Pharm. 2006; 3(5): 496-506.
19. Levin YS, Albers MJ, Butler TN, Spielman D, Peehl DM, Kurhanewicz J. Methods for metabolic evaluation of prostate cancer cells using proton and (13)C HR-MAS spectroscopy and [3-(13)C] pyruvate as a metabolic substrate. Magn. Reson. Med. 2009; 62(5): 1091-1098.
20. Swanson MG, Keshari KR, Tabatabai ZL, Simko JP, Shinohara K, Carroll PR, Zektzer AS, Kurhanewicz J. Quantification of choline- and ethanolamine-containing metabolites in human prostate tissues using (1)H HR-MAS total correlation spectroscopy. Magn. Reson. Med. 2008; 60(1): 33-40.
21. Swanson MG, Vigneron DB, Tabatabai ZL, Males RG, Schmitt L, Carroll PR, James JK, Hurd RE, Kurhanewicz J. Proton HR-MAS spectroscopy and quantitative pathologic analysis of MRI/3D-MRSI-targeted postsurgical prostate tissues. Magn. Reson. Med. 2003; 50(5): 944-954.
22. 1H HR-MAS spectroscopy. Magn. Reson. Med. 2006; 55(6): 1257-1264.
23. Santos CF, Kurhanewicz J, Tabatabai ZL, Simko JP, Keshari KR, Gbegnon A, Santos RD, Federman S, Shinohara K, Carroll PR, Haqq CM, Swanson MG. Metabolic, pathologic, and genetic analysis of prostate tissues: quantitative evaluation of histopathologic and mRNA integrity after HR-MAS spectroscopy. NMR Biomed. 2009; 23(4): 391-398.
24. 31P magnetic resonance spectroscopy and high pressure liquid chromatography. NMR Biomed. 1992; 5(4): 185-192.
25. Swanson MG, Noworlski SM, Kurhanewicz J. Magnetic Resonance Spectroscopy and Spectroscopic Imaging of the Prostate, Breast, and Liver. Modern Magnetic Resonance, Webb GA (ed). Springer: The Netherlands 2006; 1: 1-13.
26. Zektzer AS, Swanson MG, Jarso S, Nelson SJ, Vigneron DB, Kurhanewicz J. Improved signal to noise in high-resolution magic angle spinning total correlation spectroscopy studies of prostate tissues using rotor-synchronized adiabatic pulses. Magn. Reson. Med. 2005; 53(1): 41-48.
27. Morvan D, Demidem A, Papon J, Madelmont JC. Quantitative HRMAS proton total correlation spectroscopy applied to cultured melanoma cells treated by chloroethyl nitrosourea: demonstration of phospholipid metabolism alterations. Magn. Reson. Med. 2003; 49(2): 241-248.
28. 1H MR spectroscopic imaging of the prostate gland using LCModel and a dedicated basis-set: correlation with histologic findings. Magn Reson Med. 2011; 65(2): 329-339.
29. Kurhanewicz J, Vigneron DB, Males RG, Swanson MG, Yu KK, Hricak H. The prostate: MR imaging and spectroscopy. Present and future. Radiol. Clin. North Am. 2000; 38(1): 115-138, viii-ix.
30. Cooper JF, Farid I. The role of citric acid in the physiology of the prostate. 3. Lactate/citrate ratios in benign and malignant prostatic homogenates as an index of prostatic malignancy. J. Urol. 1964; 92: 533-536.
31. 1H magnetic resonance spectroscopy and biochemical study. Magn. Reson. Med. 1993; 29(2): 149-157.
32. Cheng LL, Burns MA, Taylor JL, He W, Halpern EF, McDougal WS, Wu CL. Metabolic characterization of human prostate cancer with tissue magnetic resonance spectroscopy. Cancer Res. 2005; 65(8): 3030-3034.
33. van Asten JJ, Cuijpers V, Hulsbergen-van de Kaa C, Soede-Huijbregts C, Witjes JA, Verhofstad A, Heerschap A. High resolution magic angle spinning NMR spectroscopy for metabolic assessment of cancer presence and Gleason score in human prostate needle biopsies. Magma, 2008; 21(6): 435-442.
34. 31P magnetic resonance spectroscopy. J. Urol. 1993; 150(6): 2019-2024.
35. 31P magnetic resonance spectroscopy after combined hyperthermia and radiation. Curr. Eye Res. 1994; 13(2): 151-156.
36. 31phosphorus magnetic resonance spectroscopy: a preliminary report. J. Urol. 1991; 146(1): 66-74.
37. Narayan P, Kurhanewicz J. Magnetic resonance spectroscopy in prostate disease: diagnostic possibilities and future developments. Prostate Suppl. 1992; 4: 43-50.
38. Swanson MG, Vigneron DB, Tran TK, Kurhanewicz J. Magnetic resonance imaging and spectroscopic imaging of prostate cancer. Cancer Invest. 2001; 19(5): 510-523.
39. van As NJ, de Souza NM, Riches SF, Morgan VA, Sohaib SA, Dearnaley DP, Parker CC. A study of diffusion-weighted magnetic resonance imaging in men with untreated localised prostate cancer on active surveillance. Eur. Urol. 2009; 56: 981-988.
40. Sakr WA, Tefilli MV, Grignon DJ, Banerjee M, Dey J, Gheiler EL, Tiguert R, Powell IJ, Wood DP. Gleason score 7 prostate cancer: a heterogeneous entity? Correlation with pathologic parameters and disease-free survival. Urology, 2000; 56(5): 730-734.
41. Han M, Snow PB, Epstein JI, Chan TY, Jones KA, Walsh PC, Partin AW. A neural network predicts progression for men with gleason score 3+4 versus 4+3 tumors after radical prostatectomy. Urology, 2000; 56(6): 994-999.
42. 1H HR-MAS and genomic analysis of human tumor biopsies discriminate between high and low grade astrocytomas. NMR Biomed. 2009; 22(6): 629-637.
43. Chung LW, Huang WC, Sung SY, Wu D, Odero-Marah V, Nomura T, Shigemura K, Miyagi T, Seo S, Shi C, Molitierno J, Elmore J, Anderson C, Isotani S, Edlund M, Hsieh CL, Wang R, Shehata B, Zhau HE. Stromal-epithelial interaction in prostate cancer progression. Clin. Genitourin. Cancer, 2006; 5(2): 162-170.
44. Cunha GR, Ricke W, Thomson A, Marker PC, Risbridger G, Hayward SW, Wang YZ, Donjacour AA, Kurita T. Hormonal, cellular, and molecular regulation of normal and neoplastic prostatic development. J. Steroid Biochem. Mol. Biol. 2004; 92(4): 221-236.
45. Efstathiou E, Logothetis CJ. A new therapy paradigm for prostate cancer founded on clinical observations. Clin. Cancer Res. 2010; 16(4): 1100-1107.
46. Zhong W, Peng J, He H, Wu D, Han Z, Bi X, Dai Q. Ki-67 and PCNA expression in prostate cancer and benign prostatic hyperplasia. Clin. Invest. Med. 2008; 31(1): E8-E15.
47. Smith TA, Bush C, Jameson C, Titley JC, Leach MO, Wilman DE, McCready VR. Phospholipid metabolites, prognosis and proliferation in human breast carcinoma. NMR Biomed. 1993; 6(5): 318-323.
48. Yu KK, Scheidler J, Hricak H, Vigneron DB, Zaloudek CJ, Males RG, Nelson SJ, Carroll PR, Kurhanewicz J. Prostate cancer: prediction of extracapsular extension with endorectal MR imaging and three-dimensional proton MR spectroscopic imaging. Radiology, 1999; 213(2): 481-488.
49. Yu KK, Hricak H, Alagappan R, Chernoff DM, Bacchetti P, Zaloudek CJ. Detection of extracapsular extension of prostate carcinoma with endorectal and phased-array coil MR imaging: multivariate feature analysis. Radiology, 1997; 202(3): 697-702.
50. Wang L, Hricak H, Kattan MW, Chen HN, Scardino PT, Kuroiwa K. Prediction of organ-confined prostate cancer: incremental value of MR imaging and MR spectroscopic imaging to staging nomograms. Radiology, 2006; 238(2): 597-603.
51. Marandola P, Bonghi A, Jallous H, Bombardelli E, Morazzoni P, Gerardini M, Tiscione D, Albergati F. Molecular biology and the staging of prostate cancer. Ann. NY Acad. Sci. 2004; 1028: 294-312.
52. Burns MA, He W, Wu CL, Cheng LL. Quantitative pathology in tissue MR spectroscopy based human prostate metabolomics. Technol. Cancer Res. Treat. 2004; 3(6): 591-598.
53. Hambrock T, Somford DM, Hoeks C, Bouwense SA, Huisman H, Yakar D, van Oort IM, Witjes JA, Futterer JJ, Barentsz JO. Magnetic resonance imaging guided prostate biopsy in men with repeat negative biopsies and increased prostate specific antigen. J. Urol. 2010; 183(2): 520-527.